التفاصيل البيبلوغرافية
العنوان: |
Antiobesity Pharmacotherapy: New Drugs and Emerging Targets. |
المؤلفون: |
Kim, GW, Lin, JE, Blomain, ES, Waldman, SA |
المصدر: |
Clinical Pharmacology & Therapeutics; Jan2014, Vol. 95 Issue 1, p53-66, 14p |
مصطلحات موضوعية: |
OBESITY, PANDEMICS, MEDICAL economics, DRUG therapy, CARDIOVASCULAR diseases, PEOPLE with mental illness, CARE of people, ANTIOBESITY agents |
مستخلص: |
Obesity is a growing pandemic, and related health and economic costs are staggering. Pharmacotherapy, partnered with lifestyle modifications, forms the core of current strategies to reduce the burden of this disease and its sequelae. However, therapies targeting weight loss have a significant history of safety risks, including cardiovascular and psychiatric events. Here, evolving strategies for developing antiobesity therapies, including targets, mechanisms, and developmental status, are highlighted. Progress in this field is underscored by Belviq (lorcaserin) and Qsymia (phentermine/topiramate), the first agents in more than 10 years to achieve regulatory approval for chronic weight management in obese patients. On the horizon, novel insights into metabolism and energy homeostasis reveal guanosine 3′,5′-cyclic monophosphate (cGMP) signaling circuits as emerging targets for antiobesity pharmacotherapy. These innovations in molecular discovery may elegantly align with practical off-the-shelf approaches, leveraging existing approved drugs that modulate cGMP levels for the management of obesity.Clinical Pharmacology & Therapeutics (2013); 95 1, 53-66 advance online publication 13 November 2013. doi:10.1038/clpt.2013.204 [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
قاعدة البيانات: |
Complementary Index |